Alembic Pharmaceuticals is a century-old Indian pharmaceutical company that does something deceptively simple: it makes the active chemical ingredients (APIs) that go into medicines, and then turns those ingredients into the finished tablets, injections, and creams that patients actually use - all under one roof. Founded in 1907 by the Amin family in Vadodara, Gujarat, the company was demerged from its parent group and listed independently in 2011, carrying forward a tagline of “Touching Lives over 100 years”. The recurring approach that explains everything else is vertical integration paired with a deliberate pivot toward complexity - it started by mastering basic chemistry, then used that base to build branded and generic formulations for India and the world, and now systematically shifts its R&D and manufacturing muscle toward harder-to-copy products like oncology injectables, peptides, and branded therapies that promise better returns than simple generics. # Business segments A single integrated pharmaceutical engine with three customer-facing channels - branded prescriptions for Indian doctors, generic medicines for the US and international markets, and active pharmaceutical ingredients sold to other drugmakers globally - all fed by a shared R&D and manufacturing backbone. ## 1. India Branded Business: the company’s domestic prescription engine **A field force of over 5,500 medical representatives drives 136.5 million prescriptions a year from 246,000 doctors, built on a deliberate shift from acute-care medicines toward higher-value chronic and specialty therapies.** - **Prescription volume, not just sales rank** - the company ranks 21st in the Indian Pharmaceutical Market by value but 17th by prescription volume, with 208 brands across 21 marketing divisions, meaning its reach into doctor prescribing habits is deeper than its revenue share alone suggests. - **Four brands cross the billion-rupee mark** - flagship products including Azithral (an antibiotic with a 30.1% market share in its molecule group) and Althrocin (84.2% share) have each surpassed INR 1 billion in annual sales, giving the company leadership positions it can defend with brand loyalty rather than price competition. - **Specialty therapies now lead the mix** - the company was historically known for acute-care products like anti-infectives and cough-and-cold treatments, but deliberately reoriented its portfolio so that specialty segments - gynecology, cardiology, gastroenterology, and anti-diabetic - now drive growth and consistently outpace the broader market, creating what management calls “specialty-infused sustainability”. - **Animal health is a quiet growth driver** - operating within the India business, the animal health division is the market leader in haematinics and antibiotics for livestock and poultry, with 6 brands above INR 300 million in annual sales and 21% growth in FY25, giving the company a second domestic engine that rides on the same distribution infrastructure. - **Supply reliability is the silent moat** - a new greenfield manufacturing facility in Pithampur near Indore was commissioned in April 2025 at an investment of roughly Rs. 205 crore, moving production that was previously outsourced to third parties in-house and improving logistics and operating efficiency for the domestic business. ## 2. US Formulation Business: the complex-generics and emerging branded play **The company sells 178 generic products in the United States through a direct front-end established in 2015, and has now begun layering a branded prescription business on top with the launch of its first FDA-approved branded drug, Pivya.** - **Filling rates built trust with buyers** - during the pandemic, when supply chains broke for many manufacturers, Alembic sustained a 97-98% fill rate on its US orders, earning a reputation as an organization that “delivers on its commitment” and securing shelf space that persists even as pricing pressure intensifies. - **Fewer filings, harder products** - the company has deliberately cut its ANDA (Abbreviated New Drug Application) filing rate from 20-25 per year to about 15, but the proportion of complex products - injectables, ophthalmics, dermatology, and inhalation - has risen, because harder-to-make generics face less competition and hold their pricing better. - **The branded bet is small and surgical** - rather than building a large primary-care sales force, the company is making a “calibrated strategic entry” into US branded medicines with a focused go-to-market model, starting with Pivya, a treatment for uncomplicated urinary tract infections acquired through the purchase of Utility Therapeutics Limited in 2025 for approximately $12 million in staggered payments. - **Inhalation and injectables open new doors** - the company launched its first inhalation product, Formoterol, in the US in 2022, and is investing in oncology injectables and peptides, moving into dosage forms that require specialized manufacturing and have higher barriers to entry than oral solids. ## 3. Ex-US Formulation Business: the global footprint outside America **Operating in more than 40 countries through a mix of subsidiaries, distributor partnerships, and joint ventures, this business contributes 21% of total revenue and is built on a “first generic to launch” strategy that captures market share as patents expire.** - **Partnerships in every major region** - the company has active tie-ups in Europe, Canada, Australia, Brazil, Chile, and South Africa, and has recently incorporated subsidiaries in Thailand, the Philippines, and Germany to move from distributor relationships toward direct presence in promising markets. - **Smaller European nations offer stability** - rather than competing head-to-head in large European tender markets, the company targeted smaller nations where it could build predictable, relationship-based revenue with distributors, and now has a presence in over 20 European countries. - **Chile shows the playbook** - in the two years leading up to FY25, the company filed 115 product registrations in Chile, received approval for all 115, and commercialized 40 of them, demonstrating a systematic approach of filing broadly and then activating products as market conditions warrant. - **Canada gets a dedicated vehicle** - in June 2026, Alembic signed a shareholders’ agreement to take a 45% stake in a newly incorporated Canadian company, creating a dedicated platform for development, commercialization, and distribution in the Canadian market rather than relying solely on third-party partners. ## 4. Active Pharmaceutical Ingredients (API) Business: the chemical backbone **The company manufactures the active chemical ingredients that go into medicines - both for its own formulation factories and for external customers in over 60 countries - with 149 US Drug Master Filings and a strategy focused on older molecules that remain relevant but have few competitors.** - **Backward integration that pays for itself** - roughly 32% of API output is consumed in-house by Alembic’s own formulation units, giving the company control over quality and supply timing, while the remaining 68% is sold to other drugmakers, turning a cost centre into a 16%-of-revenue business. - **Underpopulated molecules, not blockbusters** - the API division deliberately targets “old molecules which are relevant today but remain relatively underpopulated,” meaning drugs that are off-patent and essential but have few manufacturers, allowing the company to compete on supply reliability rather than price alone. - **Peptides are the next frontier** - a dedicated peptide API group is developing high-value injectable therapies, and a new peptide manufacturing block is scheduled to commence operations, with the goal of creating a vertically integrated chain from peptide API to finished injectable - a capability few companies possess. - **Volume is the lever, not price** - growth in the API business is driven primarily by volumes, with pricing a persistent headwind, so the company’s response focuses on cost improvement, portfolio choices, and capturing opportunities where its development and manufacturing strengths provide a better economic profile. # Manufacturing and R&D backbone **Ten manufacturing facilities and two R&D centres form a shared infrastructure layer that supplies all three customer-facing channels, with a deliberate shift toward complex technologies like nanoparticle injectables and spray-dried oncology products.** - **Five USFDA-approved formulation plants** - the facilities at Panelav, Karkhadi, and Jarod cover oral solids, oncology injectables, general injectables, ophthalmics, and dermatology, with the flagship F1 plant at Panelav cleared by the USFDA with zero observations in its most recent audit. - **R&D spends 9.6% of sales on complexity** - a team of 875 professionals across Vadodara and Hyderabad focuses on first-to-file opportunities, novel polymorphs (new crystal forms of existing drugs that can create intellectual property advantages), and difficult-to-make products like solid dispersion formulations that require specialized equipment and know-how. - **Contract manufacturing fills the new plants** - the F2 oncology and F3 injectables facilities, which were previously underutilized while awaiting regulatory approvals, are now operating at much higher occupancy levels thanks to signed contract manufacturing deals, turning fixed-cost burdens into revenue-generating assets. - **Sustainability is engineered into operations** - a 24 MW solar park at Bhatpur, a target of water neutrality by 2027 (with 81% of treated water already recycled and 112 recharge wells developed), and a Net Zero by 2050 commitment approved by the Science Based Targets initiative mean the manufacturing backbone is being future-proofed against resource constraints. # Group structure and partners **Alembic Pharmaceuticals Limited is the listed Indian entity, held by promoter company Nirayu Limited, with a network of wholly owned subsidiaries across the US, Europe, Australia, Latin America, and now Southeast Asia that serve as local marketing and distribution arms.** - **US subsidiary is the largest international vehicle** - Alembic Pharmaceuticals Inc. handles the US generics and branded business, acquired Utility Therapeutics Ltd. in 2025, and has access to a $22 million term loan facility guaranteed by the parent. - **Rhizen Pharmaceuticals is the research associate** - Alembic holds a 50% stake in Rhizen Pharmaceuticals SA, a Swiss-based new chemical entity research company whose drug Umbralisib became the first product developed in India to receive USFDA approval and be commercialized, and whose Tenalisib molecule was out-licensed for Greater China in a deal valued at up to $149.5 million plus royalties. - **Aleor Dermaceuticals was absorbed** - originally a 60:40 joint venture for dermatology products, Alembic bought out its partner in 2022 and merged Aleor into the parent company, bringing its USFDA-inspected dermatology facility at Karakhadi fully in-house as the F5 plant. - **Recent subsidiaries signal geographic ambition** - new entities incorporated in Thailand, the Philippines, and Germany in early 2026, plus a 45% stake in a Canadian platform company, show a pattern of moving from distributor relationships to direct or joint-venture presence in markets with long-term potential.